Immunomic Therapeutics at the 2010 OneMedForum
Dr. William G. Hearl, CEO of Immunomic Therapeutics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Video
Clarient, Inc. at the 2010 OneMedForum
Ron Andrews, CEO of Clarient, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Strategic Medicine at the 2010 OneMedForum
Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
TapImmune, Inc. at the 2010 OneMedForum
Denis Corin, President of TapImmune, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Jeff Eliot Margolis CFO of Xintria Pharmaceutical Corporation
Jeff Eliot Margolis, CFO of Xintria Pharmaceutical Corporation, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
[Company Profile] Pico-Tesla Magnetic Therapies
Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.
DATATRAK: Low Valuation, Improving Results
DATATRAK International Inc. (OTC: DATA.PK) is a clinical trials information technology (IT) and services company that is focused on increasing its share of an estimated $720 million (M) Electronic Data Capture (EDC) market opportunity.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.